20 Happy in 2021 Module 10 | ASCRS
20-Happy in 2021

20 happy in 2021 Module 10

Program Chairs

David Chang MD

David Chang, MD

Co-Moderator

Kendall Donaldson, MD

Co-Moderator

Faculty

Julie Schallhorn, MD

William  Trattler, MD

Richard Tipperman, MD

Panelists

Quentin B. Allen, MD

Zaina Al-Mohtaseb, MD

Steven Dell, MD

Rudy Nuijts, MD

Continuing Medical Education (CME) Credits

Accreditation Statement

The American Society of Cataract and Refractive Surgery is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality and scientific integrity of the CME activity.

Designation Statement
The American Society of Cataract and Refractive Surgery designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience
Refractive surgeons, anterior segment specialists, comprehensive ophthalmologists, residents, and fellows

Educational Objectives

Upon completion of this program, participants should be able to:

  • Compare and contrast new Presbyopia-correcting IOLs.
  • Compare refractive IOLs and provide practical pearls and pitfalls for implanting different refractive IOLs. 
  • Examine preoperative diagnostics and discuss selecting patients and determining the best individual refractive IOL choice. 
  • Summarize new information and changes to intraoperative refractive technology.
  • Discuss management of unhappy refractive IOL patients and refractive or surgical complications

Claim CME/CE Credits

Attendees will be able to evaluate this webinar electronically. At the conclusion of the program, attendees follow the link to the program evaluation and credit claim. Please contact Janell John, ASCRS CME Coordinator, at  
jjohn@ascrs.org with any questions on credit claims. 


Scientific Integrity and Financial Interest Disclosure

Financial Interest Disclosures for all faculty are available within the Financial Interest section of the 20/Happy website. ASCRS is committed to ensuring that all continuing medical education (CME) information is based on the application of research findings and the implementation of evidence-based medicine. ASCRS seeks to promote balance, objectivity and absence of commercial bias in its content. All persons in a position to control the content of this activity must disclose all relevant financial interests. ASCRS has mechanisms in place to mitigate all conflicts of interest prior to an educational activity being delivered to learners. 

All faculty members are required to disclose whether they, or their spouses, have any financial interest (or lack thereof) from the past 24 months with a company that produces, markets, resells or distribute ophthalmic products or services consumed by, or used on, patients. Faculty members are also required to disclose such information verbally and on their first slide. 

It is an ASCRS requirement that all presenters disclose on the first slide and verbally at the beginning of any presentation whether they have any relevant financial interests from the past 24 months. Presenters are expected to give a fair and balanced presentation. 

Notice About Off-Label Use Presentations

The webinar may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. ASCRS is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASCRS of the uses, products or techniques presented.

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.